[go: up one dir, main page]

PH12013500441A1 - Materials and methods for improving gastrointestinal function - Google Patents

Materials and methods for improving gastrointestinal function

Info

Publication number
PH12013500441A1
PH12013500441A1 PH1/2013/500441A PH12013500441A PH12013500441A1 PH 12013500441 A1 PH12013500441 A1 PH 12013500441A1 PH 12013500441 A PH12013500441 A PH 12013500441A PH 12013500441 A1 PH12013500441 A1 PH 12013500441A1
Authority
PH
Philippines
Prior art keywords
materials
methods
gastrointestinal function
improving gastrointestinal
improving
Prior art date
Application number
PH1/2013/500441A
Inventor
Paul Okunieff
Sadasivan Vidyasagar
Lurong Zhang
Original Assignee
Univ Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Florida filed Critical Univ Florida
Publication of PH12013500441A1 publication Critical patent/PH12013500441A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23B—PRESERVATION OF FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES; CHEMICAL RIPENING OF FRUIT OR VEGETABLES
    • A23B2/00—Preservation of foods or foodstuffs, in general
    • A23B2/70—Preservation of foods or foodstuffs, in general by treatment with chemicals
    • A23B2/725—Preservation of foods or foodstuffs, in general by treatment with chemicals in the form of liquids or solids
    • A23B2/788—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nutrition Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Physiology (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

The subject invention provides therapeutic compositions, and uses thereof for the treatment or amelioration of injury to small intestine mucosa. In preferred embodiments, the composition comprises one or more nutrients and/or electrolytes that acquire or retain considerable absorptive capacity.
PH1/2013/500441A 2010-09-24 2011-09-26 Materials and methods for improving gastrointestinal function PH12013500441A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38631710P 2010-09-24 2010-09-24
US201161431629P 2011-01-11 2011-01-11
PCT/US2011/053265 WO2012040707A2 (en) 2010-09-24 2011-09-26 Materials and methods for improving gastrointestinal function

Publications (1)

Publication Number Publication Date
PH12013500441A1 true PH12013500441A1 (en) 2016-06-22

Family

ID=45871248

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2013/500441A PH12013500441A1 (en) 2010-09-24 2011-09-26 Materials and methods for improving gastrointestinal function

Country Status (17)

Country Link
US (7) US8993522B2 (en)
EP (5) EP2624825B1 (en)
JP (3) JP6000253B2 (en)
KR (4) KR102205124B1 (en)
CN (2) CN105663106A (en)
AP (1) AP2013006826A0 (en)
AU (2) AU2011305124B2 (en)
BR (1) BR112013006044B1 (en)
CA (1) CA2809489C (en)
EA (1) EA030970B8 (en)
ES (2) ES2805535T3 (en)
IL (1) IL277166B (en)
MX (2) MX350541B (en)
NZ (1) NZ607189A (en)
PH (1) PH12013500441A1 (en)
SG (1) SG188293A1 (en)
WO (1) WO2012040707A2 (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2805535T3 (en) 2010-09-24 2021-02-12 Univ Florida Materials and procedures to improve gastrointestinal function
KR102584819B1 (en) * 2011-01-19 2023-10-05 프랙틸 헬쓰, 인코포레이티드 Devices and methods for the treatment of tissue
IN2014DN06737A (en) * 2012-02-08 2015-05-22 Univ Florida
EP4417256A3 (en) * 2013-03-11 2024-10-23 University of Florida Research Foundation, Inc. Materials and methods for improving lung function
JP6855240B2 (en) 2013-09-27 2021-04-07 メビオン・メディカル・システムズ・インコーポレーテッド Particle beam scanning
US10675487B2 (en) 2013-12-20 2020-06-09 Mevion Medical Systems, Inc. Energy degrader enabling high-speed energy switching
US9962560B2 (en) 2013-12-20 2018-05-08 Mevion Medical Systems, Inc. Collimator and energy degrader
US9661736B2 (en) 2014-02-20 2017-05-23 Mevion Medical Systems, Inc. Scanning system for a particle therapy system
JP2017535591A (en) * 2014-11-24 2017-11-30 エントリンシック ヘルス ソリューションズ インコーポレイテッド Amino acid composition for treating disease symptoms
US20180038873A1 (en) * 2015-02-05 2018-02-08 University Of Florida Research Foundation, Inc. Use of nhe3 as a biomarker for radiation biodosimetry
US20160339086A1 (en) * 2015-05-19 2016-11-24 Suzy Cohen Compositions and methods for treating thyroid disease
US10786689B2 (en) 2015-11-10 2020-09-29 Mevion Medical Systems, Inc. Adaptive aperture
CN105685973B (en) * 2016-02-04 2018-08-24 中山大学附属第六医院 A kind of Elental
US10702590B2 (en) 2016-04-12 2020-07-07 Script Essentials, Llc Compositions and methods for treating thyroid disease
US10925147B2 (en) 2016-07-08 2021-02-16 Mevion Medical Systems, Inc. Treatment planning
WO2018025978A1 (en) * 2016-08-05 2018-02-08 国立大学法人 東京大学 Composition to be used for treating adult t cell leukemia/lymphoma and method for producing same
CN110062621B (en) 2016-10-04 2022-11-01 佛罗里达大学研究基金会公司 Amino acid composition and use thereof
US11103730B2 (en) 2017-02-23 2021-08-31 Mevion Medical Systems, Inc. Automated treatment in particle therapy
WO2019006253A1 (en) 2017-06-30 2019-01-03 Mevion Medical Systems, Inc. Configurable collimator controlled using linear motors
WO2019070753A1 (en) * 2017-10-02 2019-04-11 University Of Florida Research Foundation, Incorporated Amino acid compositions and methods for treating diarrhea
EP3691628A1 (en) 2017-10-02 2020-08-12 University of Florida Research Foundation, Incorporated Materials and methods for inhibiting tumor growth
CN112188891A (en) * 2018-04-04 2021-01-05 佛罗里达大学研究基金会公司 Composition for treating skin
CN109601761A (en) * 2018-11-01 2019-04-12 山东大学 A kind of nutritional repairing agent for turbot enteritis
CN113811356B (en) 2019-03-08 2025-01-03 美国迈胜医疗系统有限公司 Collimators and range adjusters for particle therapy systems
WO2020219645A2 (en) * 2019-04-26 2020-10-29 Increvet, Inc. Methods for reducing the weight loss or increasing the weight of a feline in need thereof
RU2699222C1 (en) * 2019-04-29 2019-09-04 Алексей Владимирович Воронов Electrolyte salt solution for enteral infusion
WO2020251208A1 (en) * 2019-06-14 2020-12-17 씨제이제일제당 (주) Composition for preventing, treating, or improving gastrointestinal diseases comprising strain of genus corynebacterium and culture thereof
WO2021096479A1 (en) * 2019-11-11 2021-05-20 Trim-Edicine, Inc. Treatment for inflammatory bowel disease and radiation-induced intestinal injury
IT202000000442A1 (en) 2020-01-13 2021-07-13 Professional Dietetics Spa COMPOSITIONS INCLUDING AMINO ACIDS FOR USE IN THE PREVENTION AND TREATMENT OF SIDE EFFECTS OF CHEMOTHERAPY
AU2021284284A1 (en) * 2020-06-02 2022-11-17 Amilyfe, Llc Formulations and methods for treating diarrhea
JP2023533617A (en) 2020-07-02 2023-08-03 ユニバーシティ オブ フロリダ リサーチ ファウンデーション，インコーポレイティド Formulations and methods of use thereof for promoting hydration
IT202200013354A1 (en) * 2022-06-23 2023-12-23 Professional Dietetics Spa COMPOSITIONS COMPRISING AMINO ACIDS FOR USE IN THE PREVENTION AND/OR TREATMENT OF INTESTINAL DISEASES
US11878073B1 (en) 2022-09-20 2024-01-23 Entrinsic, LLC Generation of hydration-targeted formulations and methods of use therein

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1285491C (en) * 1985-09-12 1991-07-02 Robert J. Smith Method of treating catabolic dysfunction
SE8601828D0 (en) 1986-04-21 1986-04-21 Novo Industri As ENTERAL DIET PRODUCT AND AGENT FOR PRODUCTION THEREOF
US5254572A (en) * 1987-11-27 1993-10-19 Vesta Medicines (Pty) Ltd. Method and composition for supplementing vitamin B6 where the PN-PLP pathway is disturbed
US5290538A (en) 1988-12-22 1994-03-01 Skrezek Christian Nephro protective infusion solutions
WO1994017370A2 (en) 1991-03-05 1994-08-04 Miris Medical Corporation Method and device for correcting the drift offset of a pressure sensor of a flowmeter
DK0592540T3 (en) 1991-07-02 2000-06-26 Inhale Inc Method and apparatus for dispensing aerosolized drugs
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
US5558085A (en) 1993-01-29 1996-09-24 Aradigm Corporation Intrapulmonary delivery of peptide drugs
US5514656A (en) 1993-05-28 1996-05-07 Abbott Laboratories Method of providing enteral nutritional support for patients undergoing radiation therapy and/or chemotherapy
NZ248605A (en) * 1993-05-28 1994-12-22 Abbott Lab Enteral nutritional product comprising protein and fat
JP3177918B2 (en) * 1993-06-24 2001-06-18 日本電信電話株式会社 Routing equipment for packet switches
US6051256A (en) 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
US5780451A (en) * 1994-04-01 1998-07-14 Abbott Laboratories Nutritional product for a person having ulcerative colitis
JPH07330583A (en) * 1994-06-03 1995-12-19 Terumo Corp Liquid preparation containing free glutamic acid
JPH0873351A (en) * 1994-06-30 1996-03-19 Ajinomoto Co Inc Nutritive composition for inflammatory intestinal disease
EP0689835A3 (en) 1994-06-30 1996-04-17 Ajinomoto Kk Composition comprising a mixture of amino acids and at least one N-3 fatty acid
JP4011638B2 (en) * 1994-12-27 2007-11-21 イーエヌ大塚製薬株式会社 Oral enteral nutrition composition
CN1175887A (en) 1995-02-23 1998-03-11 诺瓦蒂斯营养有限公司 Amino acid composition and use thereof in clinical nutrition
AU706195B2 (en) 1995-04-14 1999-06-10 Inhale Therapeutic Systems Powdered pharmaceutical formulations having improved dispersibility
US6673355B1 (en) 1995-06-14 2004-01-06 Baylor College Of Medicine Rotavirus enterotoxin NSP4 and methods of using same
JPH11507831A (en) 1995-06-14 1999-07-13 ベイラー・カレッジ・オブ・メディスン Rotavirus enterotoxin NSP4 and method using the same
US5821217A (en) * 1995-10-27 1998-10-13 Beth Israel Deaconess Medical Center, Inc. Enteral formulation: low in fat and containing protein hydrolysates
AU6014098A (en) 1996-12-31 1998-07-31 Inhale Therapeutic Systems Aerosolized hydrophobic drug
JP2002542145A (en) 1998-11-13 2002-12-10 チルドレンズ・ホスピタル・オヴ・ロス・アンジェルス How to promote vascular growth
JP2002532520A (en) 1998-12-22 2002-10-02 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル Compounds and methods for airway disease treatment and airway drug delivery
GB0009056D0 (en) * 2000-04-12 2000-05-31 Nestle Sa Composition comprising free amino acids
US6956023B1 (en) * 2001-04-19 2005-10-18 University Of Florida Materials and methods for providing nutrition to neonates
JP4255656B2 (en) 2001-09-17 2009-04-15 株式会社メニコン Ophthalmic solution and contact lens solution
US20030105104A1 (en) 2001-11-27 2003-06-05 Burzynski Stanislaw R. Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy
US20030143293A1 (en) 2002-01-31 2003-07-31 Sergei Shushunov Compositions and methods for treating diarrhea
JP2004123642A (en) 2002-10-04 2004-04-22 Shimizu Pharmaceutical Co Ltd Electrolyte composition
DK175877B1 (en) 2002-11-11 2005-05-09 Pharmalett As Preparations for use as a therapeutic agent
US20040213838A1 (en) 2003-04-24 2004-10-28 Mazer Terrence B. Medical food tablets containing free amino acids
US20050100637A1 (en) 2003-11-12 2005-05-12 Robert Murray Carbohydrate and electrolyte replacement composition
WO2006049286A1 (en) 2004-11-02 2006-05-11 Ajinomoto Co., Inc. Preventive/remedy for allergic diseases
US20070010459A1 (en) 2005-01-14 2007-01-11 Ying Liu Application of asiatic acid and its derivatives to treat pulmonary fibrosis
GB0503337D0 (en) 2005-02-17 2005-03-23 Glaxosmithkline Biolog Sa Compositions
JP4811576B2 (en) 2005-03-31 2011-11-09 味の素株式会社 Moisture electrolyte supplement drink
EP1920770A4 (en) 2005-07-01 2010-09-29 Ajinomoto Kk Therapeutic agent for inflammatory bowel disease and tnf- alpha production inhibitor
US7595079B2 (en) 2005-07-08 2009-09-29 Bomac Vets Plus, Inc. Nutritional conjunctive support therapy for recovery in animals following stress or illness
JP4512013B2 (en) 2005-09-07 2010-07-28 和光堂株式会社 Liquid beverage composition and method for producing the same
US20070202058A1 (en) 2006-02-27 2007-08-30 Calwood Nutritionals, Inc. Compositions for treating gastric reflux
CN100522183C (en) 2006-03-02 2009-08-05 上海交通大学 Earthworm acidic-part medicine for treating cough asthma disease and preparing method
EP1864692A1 (en) 2006-06-07 2007-12-12 Biotempt B.V. Use of peptides for the control of radiation injury
DE102006018293A1 (en) 2006-04-20 2007-10-25 Fresenius Kabi Deutschland Gmbh Pediatric amino acid solution for parenteral nutrition
US20070270355A1 (en) * 2006-05-11 2007-11-22 Garcia Ramon D Sport drink containing amino acids and carbohydrates
CN101437413A (en) 2006-05-12 2009-05-20 可口可乐公司 Beverage preservatives
JP5100033B2 (en) 2006-05-16 2012-12-19 大塚製薬株式会社 Gastrointestinal and renal atrophy inhibitor
GB0612671D0 (en) * 2006-06-27 2006-08-09 Shs Int Ltd Nutritional formulation
PL2164349T3 (en) 2006-08-04 2015-03-31 Shs Int Ltd Protein free formula
KR20100057630A (en) 2007-08-03 2010-05-31 아미노테크 에이에스 Amino acid and peptide products
KR101325374B1 (en) 2008-02-19 2013-11-08 가부시키가이샤 오츠까 세이야꾸 고죠 Oral or enteral composition useful for recovery of physical functions
US20090318556A1 (en) 2008-05-15 2009-12-24 Idle Jeffrey R Biomarkers for detecting radiation exposure: methods and uses thereof
JP5576097B2 (en) 2009-11-17 2014-08-20 大塚製薬株式会社 Airway resistance improver
IT1396935B1 (en) 2009-11-26 2012-12-20 Solartium Entpr Ltd USE OF A COMBINATION FOR THE TREATMENT OF MUCOSITES INDUCED BY RADIATION OR CHEMOTHERAPY
CN101779750A (en) * 2010-03-24 2010-07-21 舒世洪 Piglet preweaning feed and preparation method thereof
WO2011127056A2 (en) 2010-04-05 2011-10-13 The Uab Research Foundation Biomarkers for assessing exposure to ionizing radiation and absorbed dose
WO2012020357A1 (en) 2010-08-09 2012-02-16 Advinus Therapeutics Ltd. Acetamide compounds, their process and pharmaceutical application
ES2805535T3 (en) * 2010-09-24 2021-02-12 Univ Florida Materials and procedures to improve gastrointestinal function
US20120321729A1 (en) 2011-06-15 2012-12-20 Ven Subbiah Nutritional formula for managing chronic obstructive pulmonary disease (copd) and lung health
US8557301B2 (en) 2011-07-01 2013-10-15 Drip Drop, Inc. Oral rehydration composition
IN2014DN06737A (en) 2012-02-08 2015-05-22 Univ Florida
PL2833891T3 (en) 2012-04-05 2019-01-31 University Of Florida Research Foundation, Inc. Compostion for treatment of cystic fibrosis and for induction of ion secretion
EP4417256A3 (en) 2013-03-11 2024-10-23 University of Florida Research Foundation, Inc. Materials and methods for improving lung function
CA3010556C (en) 2016-01-06 2020-03-10 Parasonic Ltd. Device and method for damaging parasites using ultrasonic reflection
CN110062621B (en) 2016-10-04 2022-11-01 佛罗里达大学研究基金会公司 Amino acid composition and use thereof

Also Published As

Publication number Publication date
IL277166A (en) 2020-10-29
KR102205124B1 (en) 2021-01-20
EP2624825A4 (en) 2014-02-19
SG188293A1 (en) 2013-04-30
KR20180132974A (en) 2018-12-12
AP2013006826A0 (en) 2013-04-30
JP6000253B2 (en) 2016-09-28
CN103153298B (en) 2015-11-25
US20190307724A1 (en) 2019-10-10
IL277166B (en) 2021-06-30
EP2624825B1 (en) 2017-06-14
JP2016222712A (en) 2016-12-28
WO2012040707A2 (en) 2012-03-29
EP3970715A1 (en) 2022-03-23
US11752132B2 (en) 2023-09-12
CA2809489C (en) 2017-10-24
JP6425356B2 (en) 2018-11-21
US20150196534A1 (en) 2015-07-16
EA030970B1 (en) 2018-10-31
AU2011305124A1 (en) 2013-03-14
NZ607189A (en) 2015-04-24
ES2805535T3 (en) 2021-02-12
KR20170084354A (en) 2017-07-19
US20210196679A1 (en) 2021-07-01
EP2624825A2 (en) 2013-08-14
WO2012040707A3 (en) 2012-07-05
EP4406557A3 (en) 2025-06-18
EP3173079A1 (en) 2017-05-31
US8993522B2 (en) 2015-03-31
AU2015207919B2 (en) 2017-03-02
US12239633B2 (en) 2025-03-04
JP2019011361A (en) 2019-01-24
US20240024286A1 (en) 2024-01-25
ES2639888T3 (en) 2017-10-30
KR20200009145A (en) 2020-01-29
US20120077748A1 (en) 2012-03-29
AU2011305124B2 (en) 2015-04-30
EP3494969B1 (en) 2024-03-13
EP3173079B1 (en) 2020-04-22
BR112013006044B1 (en) 2022-03-29
CN105663106A (en) 2016-06-15
JP2013542195A (en) 2013-11-21
BR112013006044A2 (en) 2016-06-07
US10940137B2 (en) 2021-03-09
EP3494969A1 (en) 2019-06-12
JP6698777B2 (en) 2020-05-27
MX350541B (en) 2017-09-08
AU2015207919A1 (en) 2015-08-20
EP4406557A2 (en) 2024-07-31
KR102069790B1 (en) 2020-01-23
US20250248972A1 (en) 2025-08-07
CN103153298A (en) 2013-06-12
KR101758424B1 (en) 2017-07-14
EA030970B8 (en) 2019-01-31
US10322109B2 (en) 2019-06-18
CA2809489A1 (en) 2012-03-29
US20190046504A1 (en) 2019-02-14
KR20130108308A (en) 2013-10-02
EA201300323A1 (en) 2014-03-31
MX2013003282A (en) 2013-05-09

Similar Documents

Publication Publication Date Title
PH12013500441A1 (en) Materials and methods for improving gastrointestinal function
PH12021550756A1 (en) Compositions and methods for treating and/or preventing cardiovascular disease
MX2013004061A (en) Cyclosporin analogs.
CL2013000018A1 (en) Compounds derived from indolizine, their preparation procedure; pharmaceutical composition; and use in the treatment of cancer, among others.
IN2012DN01920A (en)
PH12013500467A1 (en) Pharmaceutical composition
MX2019000225A (en) Compositions and methods for treatment of autoimmune and other disease.
WO2012088266A3 (en) Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
MY153039A (en) Thioacetate compounds,compositions and methods of use
WO2012055567A3 (en) Use of malononitrilamides in neuropathic pain
IN2012DN02645A (en)
SG10201408158SA (en) Composition and methods used during anti-hiv treatment
WO2014062720A3 (en) Methods of treating cancer
ZA201207377B (en) Composition comprising probiotic bacteria for use in the treatment of immune disorders
MX2009009079A (en) Engineered anti-il-23p19 antibodies.
MX2012007933A (en) Topical transdermal dexmedetomidine compositions and methods of use thereof.
WO2009095261A3 (en) Vaccine compositions
MX2013004062A (en) Cyclosporin analogs.
MX368543B (en) MATERIALS and METHODS FOR TREATING DIARRHEA.
WO2011091154A3 (en) Use of human erythrocytes for prevention and treatment of cancer dissemination and growth
MX2015001648A (en) Compositions comprising spicamycin derivatives and methods of use thereof.
WO2011106378A3 (en) Oral b12 therapy
WO2011127482A3 (en) Modulation of histone deacetylases for the treatment of metabolic disease, methods and compositions related thereto
WO2012119045A3 (en) Compositions and uses thereof to ameliorate pain
WO2011161465A3 (en) Composition for treatment of skin